数据链接：
官方服务：
资源简介：
Trastuzumab-treated HER2+/ER+ tumorsh.
应用场景：
创建时间：
2021-05-05
相关数据集
BRD8 is a therapeutic vulnerability for overcoming resistance to dual ER/HER2 blockade therapy in HR+/HER2+ breast cancer
.rda file for Seurat object of scRNA-seq data from BT474 breast cancer cell lines treated with DMSO, Neratinib, Fulvestrant, and a combination of Neratinib and Fulvestrant.
Zenodo2023-05-04 更新30
Supplementary Table S3 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Gene set enrichment analysis on Hallmark gene sets, on genes ranked based on the correlation between gene expression and FDG-PET uptake described by SUVmax (positive normalized enrichment score – NES
Figshare2025-01-06 更新10
Nuclear factor kappa B activation-induced anti-apoptosis renders HER2 positive cells drug resistant and accelerates tumor growth
Nuclear factor kappa B activation-induced anti-apoptosis renders HER2 positive cells drug resistant and accelerates tumor growth
ChEBI2014-02-13 更新00
RNA-seq of MMTV-Neu AXL KO tumors
AXL is activated by its ligand GAS6 and is expressed in triple-negative breast cancer cells. We report that AXL is also detected in HER2+ breast cancer specimens where its expression correlates with p
NIAID Data Ecosystem30
HER2 3-class classification performance using IHC and H&E images (BCI dataset).
HER2 3-class classification performance using IHC and H&E images (BCI dataset).
NIAID Data Ecosystem10
